Effect of a single dose of dexamethasone on glucose homeostasis in healthy horses by using the combined intravenous glucose and insulin test.

Sustained dexamethasone administration to horses results in insulin resistance, which may predispose them to laminitis. A single dose of dexamethasone is commonly used as a diagnostic aid, yet the effect of a single dose of dexamethasone on glucose homeostasis in horses is not well defined. The objective of this study was to characterize the change in glucose dynamics over time in response to a single dose of dexamethasone. A combined glucose-insulin tolerance test (CGIT) was performed on 6 adult geldings before and at 2, 24, and 72 h postdexamethasone (40 microg/kg of BW, i.v.); a minimum of 1 wk of rest was allowed between treatments. Before any treatment, the CGIT resulted in a hyperglycemic phase followed by a hypoglycemic phase. Dexamethasone affected glucose dynamics in 3 ways: 1) at 2 h, dexamethasone shortened the ascending branch of the negative phase (P < 0.001) of the test, indicating moderate insulin resistance; 2) at 24 h, dexamethasone impaired glucose clearance by extending the positive phase and eliminating the negative phase while insulin was elevated before the CGIT, indicating a decreased response to insulin; and 3) at 72 h, dexamethasone caused a deeper nadir value (P < 0.001) compared with predexamethasone, indicating an increased response to insulin. It was concluded that dexamethasone decreased the response to insulin as early as 2 h and maximally at 24 h. At 72 h, dexamethasone caused an increased response to insulin, which was unexpected.

Placenta detachment: unexpected high concentrations of 5-hydroxytryptamine (serotonin) in fetal blood and its mitogenic effect on placental cells in bovine.

The purpose of this study was twofold: (1) to determine whether there is a profile of 5-hydroxytryptamine (5-HT, serotonin) concentrations in fetal bovine blood and tissues during pregnancy, parturition and the early neonatal period and (2) to determine whether 5-HT has a 'mitogenic' effect on cultured placentome cells in bovine. Results revealed a 5-HT concentration profile in fetal blood. Overall concentrations of 5-HT in fetal blood were 6.6 times (P< 0.001) that of adult cows and 2.8 times (P< 0.001) that of blood collected during caesarean section (from umbilical veins) and from 18-72 h old calves. Mid-term and full-term pregnancy fetuses were not statistically different from each other. Overall concentrations of 5-HT in the intestinal wall of the fetus were 4.4 times higher (P< 0.05) than in the 24 h calf. Concentration of 5-HT in full-term muscle was 3.5 times higher than in mid-term muscle and 2.8 times higher than in 24 h old calf muscle (P< 0.05). Concentrations of 5-HT in mid-term and full-term cotyledon were 4.4 times higher (P< 0.05) than in post partum cotyledon. Characterized trophoblast cells and a heterogeneous population of bovine cotyledon cells treated with 5-HT (2.5, 5.0 and 10.0 microm) incorporated between 2.0 and 3.0 times more(3)[H]-thymidine than untreated controls, indicating a dose-dependent (r=0.94) positive mitogenic effect of 5-HT. Both groups of cultured cells responded equally. Five-HT treatment did not affect either cell number or cell size. It was concluded that a 5-HT concentration profile exists in fetal bovine blood and tissues and that 5-HT has the ability to act as a mitogen in bovine placental cells.

Reduced cortisol potentiates the exercise-induced increase in corticotropin to a greater extent in trained compared with untrained men.

We examined the effect of acute exercise and reduced cortisol on pituitary and adrenal responsiveness and the impact of reduced plasma cortisol on maximal oxygen consumption (VO2max) in eight trained (T) and eight untrained (UT) males. Subjects completed two graded maximal exercise tests (GXT), each preceded by either overnight metyrapone (MET) or placebo (PLA) administration. Blood samples were collected before and after GXT. With PLA, resting corticotropin (ACTH) levels were higher in T versus UT men; however, cortisol and 11-deoxycortisol were similar between groups. Following GXT on PLA, cortisol was unchanged but 11-deoxycortisol increased in both groups; however, ACTH increased only in UT men. For both groups, cortisol, 11-deoxycortisol, and ACTH were different post-GXT with MET versus PLA. Furthermore, following GXT with MET, the ACTH response was greater in T versus UT subjects. VO2max was not altered by MET in either group. We conclude that (1) at rest, only ACTH levels differed between T and UT men; (2) individually, the GXT and MET provide a similar ACTH response in UT but not in T subjects; (3) when GXT and MET are superimposed, they provide a stronger stimulus to pituitary and adrenal reserve than either test alone; (4) the combination of MET and GXT elicits a greater ACTH response in T compared with UT men; and (5) an acute reduction in plasma cortisol does not alter VO2max.

Evaluation of inhibitory effects of doxorubicin on collagenase using a bovine placentome model.

The chemotherapeutic antibiotic doxorubicin (Adriamycin) was reported to inhibit bacterial collagenase activity when tested on both a synthetic substrate and intact collagen. Our objective was to establish whether doxorubicin would inhibit bacterial collagenase activity on a bovine placentome model. Metabolically active, isolated bovine placentomes were infused, via umbilical vessels, with a mixture of bacterial collagenase and doxorubicin. Six experimental groups were used. Group (1) comprised of saline controls; (2), collagenase at 1,200 U/cc; (3, 4, and 5), collagenase (1,200 U/cc) plus doxorubicin at 0.04 mg/cc, 0.02 mg/cc, 0.01 mg/cc, respectively; (6), doxorubicin at 0.02 mg/cc. After 5 hrs of incubation (39 degrees C), manometric pressure (needed to separate caruncle and cotyledon), caruncle-cotyledon interface hydroxyproline (collagenolysis), and total protein (proteolysis) were determined. Results indicated no (P > 0.01) inhibition of collagenase by doxorubicin. We concluded that doxorubicin (at above dosages) is not an inhibitor for bacterial collagenase when tested on bovine placentomes.

The potential of collagenase as a new therapy for separation of human retained placenta: hydrolytic potency on human, equine and bovine placentae.

The purpose of this study was to determine to what degree bacterial collagenase may digest human placentae compared to equine and bovine placentae. Placenta samples from human, equine and bovine were incubated with bacterial collagenase solution at various concentrations. The degree of hydrolysis and collagen breakdown was measured by the release of total proteins and hydroxyproline into the incubation media. Also, whole placentae were injected via umbilical cord arteries with collagenase solution (200 U/ml, 200 ml total volume in human and 1000 ml in equine) and hydrolysis determined chemically and subjectively. Human and equine placental collagens were the most sensitive to collagenase digestion. Overall mean collagenase activity determined by the release of hydroxyproline from human placenta was 1.6 times and in equine placenta three times greater than in bovine placenta, while the breakdown of non-collagenous proteins remained negligible. When injected into whole placenta, the collagenase digested placentae evenly within 6-12 h. At 24 h, placentae were liquefied, although, umbilical blood vessels resisted collagenase digestion. Bacterial collagenase was highly effective in breaking down human placenta collagen. Intraplacental injections of collagenase via umbilical cord arteries may help to detach retained placenta in women as it does in mares and cows.

Equine retained placenta: technique for and tolerance to umbilical artery injections of collagenase.

Under laboratory conditions and in clinical experiments, bacterial collagenase has proven to be effective in hydrolyzing placenta and detaching cotyledon from caruncle in the bovine species. Laboratory studies in which placental samples were incubated with collagenase have also demonstrated that collagenase is 3.7 times more effective in hydrolyzing equine placenta than bovine placenta. This led to the hypothesis that collagenase may be a potential treatment for mares with retained placenta. However, that collagenase may hydrolyze the uterine wall and perforate the uterus was a concern. It was the purpose of this study thus to determine any adverse effects of collagenase on the equine uterus and to develop a method for intraplacental injection of collagenase. Three normally expelled intact placentas from Arabian mares, 10 cyclic mixed-breed mares, and 4 mares of various breeds with retained placenta were used. Fluoroscein dye and latex were used to study the placental vasculature and to determine a suitable dose of collagenase; placentas were hydrolyzed by collagenase solution in vitro. Bacterial collagenase solution (40,000 units, 200 ml) was infused into the uterine lumen of each cyclic mare. Uterine biopsies were obtained from the mares before collagenase infusion and again at 16 h and 26 d after infusion. In the mares with retained placenta, each placenta was infused via its umbilical cord vessels with 200,000 units of bacterial collagenase in 1 L of saline. Results showed that none of the uteri from cyclic mares were damaged by collagenase treatment. During a 4-wk period of monitoring (including endoscopy) mares with retained placenta did not show any abnormalities. Retained placentas were expelled in less than 6 h after collagenase treatment. It was concluded that intraplacental injections of collagenase are a safe and potentially effective treatment for retained placenta in mares.

Results of a combined dexamethasone suppression/thyrotropin-releasing hormone stimulation test in healthy horses and horses suspected to have a pars intermedia pituitary adenoma.

OBJECTIVE: To evaluate results of a combined dexamethasone suppression/thyrotropin-releasing hormone (TRH) stimulation test in horses suspected clinically to have a pars intermedia pituitary adenoma (PIPA). DESIGN: Case-control study. ANIMALS: 7 healthy adult horses and 5 horses suspected to have a PIPA. PROCEDURE: A baseline blood sample was collected, and dexamethasone (40 micrograms/kg [18 micrograms/lb] of body weight, IV) was administered; a second blood sample was collected 3 hours later, and TRH (1.1 mg, IV) was administered; serial blood samples were collected 15, 30, 45, 60, and 90 minutes and 21 hours after TRH administration (24 hours after dexamethasone injection). Cortisol concentration was determined for all blood samples. RESULTS: Baseline cortisol concentration was significantly lower in horses suspected to have a PIPA than in healthy horses. Cortisol concentration was suppressed by dexamethasone in both groups; however, after TRH administration, cortisol concentration returned to baseline values in horses suspected to have a PIPA, but not in healthy horses. Concentration was still less than the baseline value 24 hours after dexamethasone administration in healthy horses. CLINICAL IMPLICATIONS: The combined dexamethasone suppression/TRH stimulation test may be a useful diagnostic test in horses suspected to have a PIPA. For clinical application, collection of a blood sample 30 minutes after TRH administration is recommended.

Prevention of retained placenta by injection of collagenase into umbilical arteries of calves delivered by cesarean section: a tolerance study.

In the cow, cesarean section delivery is often followed by retention of fetal membranes. Hypothetically, the retention of fetal membranes could be prevented by intraplacental injections of the enzyme collagenase. However, the infusion of this potent proteolytic enzyme into a uterus traumatized by surgery can lead to uterine damage, including perforation. Thus, the objective of this research was to evaluate tolerance of intraplacental treatment of bacterial collagenase. A cesarean section was performed on 10 experimental cows undergoing induced delivery or diagnosed with dystocia. During the surgical procedure, 200,000 units of bacterial collagenase in 1 L of saline were infused via the umbilical arteries. A cesarean section was also performed on control cows (n = 25) affected by dystocia, but these received no collagenase. The collagenase-treated cows showed no clinical or laboratory signs of abnormality over a 3- to 4-wk observation period post treatment. When membrane retention time was set at 36 h post surgery, 20% of the experimental cows and 60% of the control cows had retained the fetal membranes. It was concluded that intraplacental administration of collagenase during cesarean section is safe. However, treatment effectiveness and economic benefits for commercial application need further study.

Evaluation of injections of collagenase and oxytetracycline via the umbilical artery as treatment for retained placenta in cattle.

OBJECTIVES: To test whether oxytetracycline inactivates collagenase when combined as a potential treatment for retained fetal membranes in cattle and to determine whether oxytetracycline passes to blood from fetal membranes after intraplacental injection. DESIGN: Prospective, controlled study. SAMPLE POPULATION: 288 placentomes from 12 cows in their third trimester of pregnancy and 4 cows at term pregnancy. PROCEDURE: 8 experimental groups were established: saline control, collagenase, collagenase plus oxytetracycline at 3 dosages, and oxytetracycline at 3 dosages. Placentomes were infused through an umbilical vessel with the test solutions and incubated at 39 C for 4 hours. Immediately after incubation, the force needed to detach cotyledons from caruncles was measured by a manometric technique. Cotyledon-caruncle interface fluids were analyzed for hydroxyproline (collagen breakdown) and total protein contents. A combination of collagenase and oxytetracycline was injected via umbilical arteries of cows undergoing cesarean section and in cows with retained fetal membranes after natural delivery. Antibiotic residue in blood was determined by the Bacillus stearothermophilus disk assay. RESULTS: There were no significant differences among collagenase and collagenase plus oxytetracycline groups in the amount of pressure needed to separate cotyledon from caruncle, amount of hydroxyproline released, and amount of total protein broken down. The 4 cows tested negative for oxytetracycline in the blood. CLINICAL RELEVANCE: Oxytetracycline and collagenase may be a potential combination treatment for retained fetal membranes in cattle. In addition, the lack of antibiotic residue detection in blood may be of regulatory relevance.

Successful treatment of retained placenta with umbilical cord injections of collagenase in cows.

Fetal membranes usually are released from the uterus between 2 and 6 postpartum hours. However, in a substantial percentage of cows (11%), fetal membranes are retained for several days. In part, failure of collagen breakdown seems to be related to retention of fetal membranes. Injections of 200,000 U of bacterial collagenase in 1,000 ml of physiologic saline solution via umbilical arteries (1 or 2) between 24 and 72 hours of retention caused release of retained fetal membranes in 23 of 27 cows (85%) with noninduced retained fetal membranes and in 10 of 14 cows (71%) with experimentally induced retained fetal membranes, within 36 hours after injection. Controls (n = 36) did not release retained fetal membranes within this time. Injections of collagenase via a jugular vein (2.2 x 10(6) U in 1,000 ml of physiologic saline solution), administered over a 30-minute period, caused release of retained fetal membranes within 36 hours in 3 of 6 cows with experimentally induced retained fetal membranes. Clinical complications did not follow treatments with collagenase. Umbilical injections of bacterial collagenase were highly effective in the treatment of retained fetal membranes in cows. The procedure is simple, safe, affordable, and can be completed in 25 minutes.

Bovine retained placenta: effects of collagenase and hyaluronidase on detachment of placenta.

A significant percentage of cows (11%) fail to release the placenta within 12 h postpartum. Failure of collagen breakdown seems to be related to the retention of placentas. Sections of placentomes incubated with bacterial collagenase caused an increase in placentome proteolysis (6.6-fold) and placentome collagenolysis (94-fold) within 4 h in a dose-related fashion (r = 0.94). Injections of collagenase (825 U/cc) into the placentomes, via umbilical vessels, decreased the cotyledon-caruncle binding force (determined by manometry) to 30 +/- 5 mm Hg from 97 +/- 2 mm Hg, and increased proteolysis by 42% within 8 h (r = -0.95). Hyaluronidase at various concentrations (400-8 250 U/cc) and at various incubation times (up to 8 h) was not effective. Hyaluronidase (825 U/cc) and collagenase (825 U/cc) were not synergistic in loosening cotyledon-caruncle attachment. A single 15-min collagenase pulse, given prior to perfusion with collagenase-free blood, was as effective in loosening cotyledon attachment as was a sustained 2-h perfusion of blood with collagenase added. It was concluded that collagenase caused collagenolysis and loosening of cotyledon from caruncle, but collagenolysis and cotyledon-caruncle separation were not facilitated by the presence of hyaluronidase.

Fine structural aspects of postnatal development of feline lung.

Lung development was studied in late prenatal, 1-, 7-, 14-, and 21-days postnatal and adult cats. Cats were born with a few alveoli, and the lungs appeared to have patches of primitive air spaces (saccules). The saccules of prenatal kittens were thick walled, very cellular, and lined by type II pneumocytes. Eosinophils were observed in the septum, intraepithelially, and in the alveolar space of growing cats. Secondary septa were flanked by a double capillary network and divided saccules into multiple shallow alveoli. Septation was irregular and time dependent and not completed by day 231 of postnatal life. Elastic fibers accumulated at the tip of the septa, seemingly playing an important role in alveolar formation. Type II pneumocytes were located at the base of the secondary septa in growing cats, thus strengthening secondary septa to withstand the stresses of respiration. Pores of Kohn were not observed in growing cats.

Clearance of exogenous carnitine in bovine semen: Potential diagnosis of epididymal function and patency of the ductus deferens.

Carnitine content in the ejaculate depends mainly on the capability of the epididymis wall to transfer carnitine from the blood and on the patency of ejaculatory ductus systems. An elevation of carnitine in semen subsequent to an intravenous injection of carnitine is expected. Intravenous injections of carnitine (L-isomer and DL-isomers) caused a significant (P <0.05) elevation (more than 10-fold) in blood carnitine. However, carnitine injection failed to increase net secretion of carnitine into the ejaculate and blood elimination half-life was 2.3 hours. Mean concentrations of carnitine in the electroejaculate (3.0 nmoles/ml) were significantly lower than in the ejaculate following natural mating (180 nmoles/ml). Vasectomy decreased net carnitine per ejaculate to about 1/5 the prevasectomy value, when ejaculate was collected following natural mating. However, vasectomy did not affect carnitine concentrations in semen collected by electroejaculation. Twenty-one percent of the carnitine in semen originated in the accessory glands and 79% in the epididymides. Carnitine in the electroejaculate was originated almost exclusively in the accessory glands. It was concluded that the diagnostic value of carnitine in semen is limited. Some considerations are: secretion of carnitine is not organ specific, there are large individual variations, there is a negative effect of electroejaculation, and a carnitine loading dose technique is not feasible. However, there is a diagnostic potential in using carnitine assay to detect epididymides occlusion, but only when ejaculate is collected by an artificial vagina.

Changes in the proportion of type I and type III collagen in the developing and retained bovine placentome.

The proportions of Type I and Type III collagen were evaluated from gestational, postpartum-retained, and released bovine placental membranes. Placentomes were excised at 90, 150, 210, and 270 days of gestation (n = 32) and from postpartum-retained (2 and 12 h, n = 8) and released (2 h, n = 4) membranes. Placentome components were processed for collagen, hydroxyproline, protein, and dry weight determination. Collagen extracts were separated by SDS-PAGE. Densitometry was used to establish the proportions of collagen alpha chains (Type I = 2 alpha 1 + 1 alpha 2; Type III = 3 alpha 1). No difference in the proportion of maternal caruncular Type I and Type III collagen was found. The proportion of Type I fetal cotyledonary collagen was lowest (p less than 0.05) at Day 90 of gestation but did not differ between Days 150, 210, 270, or between retained and released fetal membranes. The proportion of Type III fetal cotyledonary collagen was greatest (p less than 0.05) at Day 90. Retained fetal cotyledons had a greater (p less than 0.05) proportion of Type III collagen than did released fetal cotyledons. Therefore, although hydroxyproline content was not different between retained and released fetal membranes, the retained bovine fetal cotyledon was characterized by disproportionate amounts of Type III collagen as compared to the fetal cotyledon that was not retained.

Uterokinetic activity of fenprostalene (a prostaglandin F2alpha analog) in vivo and in vitro in the bovine.

The luteolytic potency of fenprostalene (a PGF2alpha analog) is about 20-times that of naturally produced PGF2alpha. The objective of this research was to investigate the uterokinetic effects of fenprostalene at a luteolytic dosage (1.0 mg) in the cyclic and early postpartum cow, and in the isolated uterine horn. Uterine motility measurements were conducted on two consecutive days in each cow. Experimental protocol on Day 1 was: spontaneous motility was recorded for 1 h; fenprostalene was injected (1.0 mg i.m.), after which motility was recorded for 2 h; fenprostalene was injected (1.0 mg i.v.) and motility was recorded for 30 min; and oxytocin was injected (40 U i.v.), followed by a 30-min recording period. On Day 2, the treatment sequence was reversed: spontaneous motility was recorded for 1 h; oxytocin was injected (100 U i.m.), after which motility was recorded for 2 h; fenprostalene was injected (1.0 mg i.v.) and motility recorded for 30 min; and oxytocin was injected (40 U i.v.), followed by a 30-min recording period. In the in vitro experiment, different dosages of fenprostalene (5.9, 11.8, 17.6, and 29.4 ng/ml bath solutions) and oxytocin (0.06, 0.12, 0.18, and 0.60 mU/ml bath solutions) were tested in pairs for 1 h. The treatment was then repeated. In a different group, fenprostalene (5.9 ng/ml bath solution) and oxytocin (0.06 mU/ml bath solution) treatments were alternated. Fenprostalene (at luteolytic dosage) was not uterokinetic in either the cyclic or postpartum cow. However, fenprostalene and oxytocin had a significant uterokinetic effect (five- to six-fold pretreatment value) on the isolated uterine horn preparation at all dosages studied. Peak motility occurred between 10 to 15 min, followed by a gradual decrease to 40% at 60 min. When the treatments were repeated at 60 min, oxytocin but not fenprostalene caused a minute, transient contraction. However, fenprostalene-desensitized (by exposure to fenprostalene) uteri reacted significantly to oxytocin, and vice versa.

Morphometric analysis of collagen in gestational and retained bovine placentomes.

Bovine placentome collagen was quantified (P<0.01) at four gestational stages (90, 150, 210 and 270 d, n = 8 d ), at 2 h post partum without (n = 4) and at 2 and 12 h post partum with (n = 8) experimentally-induced placental retention. Placentome sections were fixed and stained for collagen. Fetal cotyledonary (FC) collagen volume fraction (V(V)) increased over days of gestation studied (V(V)=0.03+/-0.01, 0.06+/-0.01, 0.13+/-0.01 and 0.19+/-0.01). Fetal cotyledonary hydroxyproline (3.15+/-0.41, 4.55+/-0.41 and 7.04+/-0.41 mg/g) and FC protein (432.0+/-17.1, 479.9+/-17.1, 585.4+/-17.1 mg/g) increased over Days 90, 150 and 210 and were similar on Days 210 and 270. Fetal cotyledonary collagen V(V) and hydroxyproline did not differ between Day 270, retained and nonretained cotyledons. Protein concentration was higher in 2 h (578.1+/-18.5 mg/g) and 12 h (526.0+/-18.5 mg/g) retained versus nonretained (400.4+/-36.2 mg/g) cotyledons. Maternal caruncular (MC) collagen V(V) and protein concentration were higher on Days 90 and 150 than on Days 210 and 270. Maternal caruncular hydroxyproline was similar from Day 90 to 210 and increased from Day 210 to 270. Maternal caruncular collagen V(V), hydroxyproline and protein concentrations were similar on Day 270 and in 2 h and 12 h retained membrane caruncles. Gestational increases in placentome collagen occurred from FC sources. No difference in FC or MC collagen V(V) existed between Day 270, retained and nonretained placentomes.

Desensitization of rabbit myometrium to oxytocin and prostaglandin F2 alpha.

The desensitizing effects of oxytocin (OT) and prostaglandin F2 alpha (PGF2 alpha) were investigated in the uteri of rabbits. Uterine motility was measured in anesthetized rabbits infused intravenously with either PGF2 alpha (50 micrograms/min) or OT (100 mU/min) alternately. The treatment sequence was saline (30 min), first drug (OT or PGF2 alpha, 90 min), second drug (OT if PGF2 alpha was first drug and vice versa, 90 min), and first drug (repeated) 60 min. Both OT and PGF2 alpha infusions increased motility approximately 200% within 5-10 min. Thereafter, motility decreased linearly to base-line value. Fifty percent desensitization was completed at 35-45 min and 100% at 90 min. A tenfold increase in the infusion rate caused no further increase in motility. However, OT infusion into a PGF2 alpha desensitized uterus (and vice versa) elicited an immediate uterokinetic response. Oxygen consumption and glucose oxidation rate of uterine slices measured at different stages (preinfusion, maximal motility, and desensitized) of uterine motility showed no difference (P greater than 0.05) between the two experimental treatments. It was concluded that either OT or PGF2 alpha infusions specifically desensitized the uterus.

Absence of uterokinetic effects of prostaglandin F 2 alpha on oxytocin-reactive uterus in the mare.

In most cyclic females, prostaglandin F(2 alpha) (PGF(2 alpha)) triggers a uterine motility response resembling that of oxytocin (OT). To determine if PGF(2 alpha) is a uterokinetic substance in the cycling mare, uterine motility was measured by intrauterine balloon technique in 12 conscious, normally cyclic mares. After 60 min of saline infusion, continuous intravenous (i.v.) infusion with OT (1 i.u./min) was followed by PGF(2 alpha) (200 microg/min) for 60 min each. The experiment was repeated 3 wk later except with PGF(2 alpha) preceding OT. A second group of mares was administered OT (60 i.u.) either i.v., intramuscularly (i.m.), or intrauterinely (i.u.). Plasma samples were studied for progesterone concentration. Control uterine motility for the first group of mares was (mean +/- SEM) 545.83 +/- 45.10 mm(2). Significant (P<0.05) elevation in uterine motility was recorded for OT (1118.60 +/- 70.56 mm(2)) regardless if PGF(2 alpha) preceded OT infusion or vice-versa. No significant difference (P>0.05) was seen in motility after PGF(2 alpha) (423.33 +/- 31.12 mm(2)) infusion. The uterokinetic effect of OT was greatest when OT was administered i.v. (1696.50 +/- 195.46 mm(2)) followed by i.m. (819.82 +/- 39.96 mm(2)), and it was least effective when administered i.u. (607.83 +/- 21.56 mm(2)) as compared to control uterine motility (279.78 +/- 22.33 mm(2)). Skin electrical resistance values rose from 0 to 2000 ohms with PGF(2 alpha) infusion (but not with OT), indicating that PGF(2 alpha) was bioactive. It was concluded that PGF(2 alpha) was not a uterokinetic substance in the cyclic mare.

Passage of exogenous L-thyroxine and triiodothyronine into bovine ejaculate.

The metabolic effects of thyroxine (T4) and triiodothyronine (T3) on spermatozoa metabolism and male anatomy have been demonstrated. The metabolic effects of T3 and T4 could affect the physiologic characteristics of the spermatozoa. There are little data on the passage of T4 and T3 into the ejaculate from blood. The passage of exogenous T4 and T3 from the blood into semen was measured after T4 (45 mg) or T3 (37.5 mg) was injected IV into 8 bulls. Blood and electroejaculate were obtained simultaneously at 20, 40, 60, 120, and 180 minutes and 24 hours after bulls were injected to determine T3 and T4 concentrations compared with base-line values. Blood T3 and T4 concentrations were increased (P less than 0.05) at 20 minutes after bulls were injected (1.1 +/- 0.25 to 598 +/- 76.3 ng/ml and from 66 +/- 5 to 1,318 +/- 105 ng/ml, respectively). Seminal concentrations of T4 were unchanged until 120 minutes after bulls were injected, when they increased (P less than 0.05) from less than 1.2 ng/ml to 4.7 +/- 1.9 ng/ml. However, seminal concentrations of T3 were increased (P less than 0.05) from less than 0.1 ng/ml to 0.5 +/- 0.2 ng/ml at 20 minutes and to 12.5 +/- 2.9 ng/ml at 120 minutes after bulls were injected. It was concluded that exogenous thyroid hormones passed into the ejaculate from blood, with T3 passing faster than T4.

Effect of electroejaculation on progesterone and cortisol excretion in bovine semen.

Artificial vagina (AV) and electroejaculation (EE) are the 2 methods used to obtain semen from bulls. The purpose in the present study was to evaluate these 2 methods of collection when 2 markers, cortisol and progesterone, were injected IV. During period 1 (control measurement), semen was obtained by EE at 0, 20, 60, 120, and 180 minutes. In period 2, bulls were injected (3 days later) with a mixture of cortisol (113 mg) and progesterone (100 mg), and then samples were obtained by EE. In period 3, cortisol and progesterone were injected (3 weeks later), and samples were obtained by AV. Seminal plasma concentrations of cortisol and progesterone were maximal at 20 minutes in EE and AV collections. Seminal plasma concentrations of progesterone and cortisol were roughly 50% less in EE than in AV collection. However, the total excretion of progesterone and cortisol per collection was similar in both techniques. Excretion of cortisol was 14 to 33 times greater than that of progesterone. It was concluded that concentrations of markers in the EE were significantly less than those in AV collection. For this reason, total excretion and concentration of marker in semen should be accounted for when conducting excretion studies.